secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001193125-25-120345
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atara Q1 net income $38M; FDA lifts EBVALLO holds; $16M offering closes May 16
------------------------------------------------------------------------------

- Net income of $38.0M ($3.50 diluted EPS) vs net loss of $31.8M in Q1 2024; revenue $98.1M, up from $27.4M, driven by Pierre Fabre milestone.
- Cash $13.8M at Mar 31, 2025; with $16M gross proceeds from May offering, expects runway into Q1 2026.
- FDA lifted clinical holds on EBVALLO; Type A meeting Q2 2025 to address CRL; plans to resume Phase 3 ALLELE study.
- Workforce reduced ~30% in May, retaining ~23 staff; FY2025 operating expenses expected to decrease ~65% YoY.
- James Huang (Panacea) and Nachi Subramanian (Redmile) appointed to board effective after offering close.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000119312525120345/0001193125-25-120345-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000119312525120345/d106735d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-120345

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer